Hong Kong · Sponsored
Decoding HER2 IHC Scoring Guidelines: Understanding Immunohistochemistry Scoring in Different Cancers
This content is sponsored by Daiichi Sankyo (Hong Kong) Limited. It is intended for healthcare professionals only.
Human Epidermal Growth Factor Receptor 2 (HER2) aberrations, such as overexpression, HER2 gene amplification, and HER2 mutations, have been extensively researched and are associated with tumor proliferation in various solid tumor types including breast cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, biliary tract cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and bladder cancer.1 The presence of HER2 aberrations is linked to reduced survival, increased chance of brain metastasis, and treatment resistance.2
